Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide a summary of the preclinical studies conducted to date for its Gastrointestinal ReProgramming (GaRP) dietary supplement as it targets commencement of a human clinical trial in 2Q 2020.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide a summary of the preclinical studies conducted to date for its Gastrointestinal ReProgramming (GaRP) dietary supplement as it targets commencement of a human clinical trial in 2Q 2020.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st December 2019. The Company's cash plus term deposits at the end of the quarter stood at $4.30m
Anatara Lifesciences (ASX:ANR) is pleased to provide an update on the protocol for its clinical trial in irritable bowel syndrome (IBS) for its GaRP dietary supplement.
Anatara Lifesciences (ASX:ANR) is pleased to provide an update on its GaRP dietary supplement preclinical milestones, which is being developed to specifically target two human gastrointestinal disorders, inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).
Anatara Lifesciences Ltd (ASX:ANR) CEO Steve Lydeamore presented to investors at the Pitt Street Research Life Sciences Conference in Sydney last month. During his presentation, Steve spoke to the Anatara story and the exciting year we have ahead with upcoming corporate milestones on both our human and animal health product opportunities.
Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, will present today at the Pitt Street Research Life Sciences Conference, held in Sydney, NSW.
Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $847,325 from the Australian Taxation Office under the Federal Government's Research and Development (R&D) tax incentive scheme.
Anatara's CEO Steve Lydeamore has been invited to present at the Pitt Street Research Life Sciences Conference on the 28th November in Sydney. Any investors interested in attending these presentations are invited to reach out.
Anatara Lifesciences Ltd (ASX:ANR) CEO Steve Lydeamore is interviewed by ABN Newswire, and talks about the human trials as well as the product pipeline for next year.
As Anatara moves forward, the Board is confident in the knowledge that a substantial market opportunity for Detach(R) remains, with more pressure than ever on producers to reduce their antibiotic use and find suitable alternatives which minimise illnesses, such as scour, on farms.
